A study on the effects of radiotherapy on hearing in patients with unilateral parotid gland tumors

Published: 29-10-2009 Last updated: 04-05-2024

1. To determine the incidence of clinical relevant hearing loss in patients who inderwent postopertaive radiation for a parotid tumor.2. To determine factors influencing hearing loss.

3. To determine the social impact of eventual hearing loss.

Ethical review Approved WMO **Status** Recruiting

Health condition type Aural disorders NEC

Study type Observational non invasive

Summary

ID

NL-OMON32836

Source

ToetsingOnline

Brief title RTototox

Condition

Aural disorders NEC

Synonym

ototoxicity hearing loss

Research involving

Human

Sponsors and support

Primary sponsor: Vrije Universiteit Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: ototoxicity, parotid tumors, radiotherapy

Outcome measures

Primary outcome

Hearing loss

Prognostic parameters of hearing loss

Social impact of hearing loss

Secondary outcome

Prognostic parameters of hearing loss

Social impact of hearing loss

Study description

Background summary

30% of the patients who were treated by surgery and radiotherapy for a partod tumor develop hearing loss. There is a dose-effect relation of radiotherapy and hearing loss. using modern radiation techniques it might be expected that hearing loss will decrease.

Study objective

- 1. To determine the incidence of clinical relevant hearing loss in patients who inderwent postopertaive radiation for a parotid tumor.
- 2. To determine factors influencing hearing loss.
- 3. To determine the social impact of eventual hearing loss.

Study design

Using audiometry and a questionnaire hearing loss was measured. The mean dose on middle ear, cochlea and Eustachian tube was estimated with a CT-planning system.

Study burden and risks

2 - A study on the effects of radiotherapy on hearing in patients with unilateral pa ... 13-05-2025

Routine audiometry and a questionairre will be used.

Contacts

Public

Vrije Universiteit Medisch Centrum

De Boelelaan 1117 1081 HV Nederland **Scientific**

Vrije Universiteit Medisch Centrum

De Boelelaan 1117 1081 HV Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- 1. Patiënts with benig or malignant parotid tumor
- 2. Unilateral treatment by surgery and postoperative radiotherapy
- 3. Treated after 01-01-2000
- 4. Treatment with curative intent
- 5. No other ototoxic treatment
- 6. No signs of recurrence and/or distant metastases

Exclusion criteria

Preexistent asymetric hearing loss

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 01-11-2009

Enrollment: 80

Type: Actual

Ethics review

Approved WMO

Date: 29-10-2009

Application type: First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL29529.029.09